Physician profile
Twyla Hurst
NPI 1083814073
$913.70
in general payments reported to CMS, 2019-2025
12 companies · $72.82 in 2025
The $72.82 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $234 · 2022: $316 · 2023: $187 · 2024: $105 · 2025: $72.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $364.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $318.12 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $206.18 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $143.03 | 2021-2024 | Jardiance, Mounjaro |
| Abbott Laboratories | $74.73 | 2021-2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $35.17 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $33.56 | 2022-2023 | |
| Amgen INC. | $20.55 | 2022 | |
| Glaxosmithkline, LLC. | $19.07 | 2022 | |
| Mylan Specialty L.P. | $19.01 | 2024 | Yupelri |
| Abbvie INC. | $16.67 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.60 | 2024 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $13.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Twyla Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.